Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis (Q74022709)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

L M Ossege

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

E Sindern

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

T Patzold

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

J P Malin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 June 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

International Immunopharmacology

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

1085-1100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

Multiple sclerosis (first of two parts).

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Corticosteroids induce expression of transforming-growth-factor-beta1 mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Influence of serum on zinc, toxic shock syndrome toxin-1, and lipopolysaccharide-induced production of IFN-gamma and IL-1 beta by human mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

A membrane-filter technique for the detection of complementary DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Detection of transforming growth factor beta 1 mRNA in cerebrospinal fluid cells of patients with meningitis by non-radioactive in situ hybridization.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

1 reference

7 January 2021

Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Recombinant Interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta augments suppressor cell function in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Transforming growth factor beta: its mechanism of action and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Suppression of immune cell function in vitro by recombinant human transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Deactivation of macrophages by transforming growth factor-β

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Phosphorylation-dependent interaction of the cytoplasmic domains of the type I and type II transforming growth factor-beta receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Distribution and modulation of the cellular receptor for transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Tumor necrosis factor (TNF).

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Shedding of tumor necrosis factor receptors by activated human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Pathogenesis of inflammatory demyelination: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

Interferon beta normalizes suppressor cell function in dysimmune neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900039-X

7 January 2021

10.1016/S1567-5769(01)00039-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11407304%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference